vegf a165 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    R&D Systems vegf a165 b
    Vegf A165 B, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegf a165 b/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    vegf a165 b - by Bioz Stars, 2021-07
    94/100 stars
      Buy from Supplier

    86
    R&D Systems vegf a165
    Vegf A165, supplied by R&D Systems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegf a165/product/R&D Systems
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    vegf a165 - by Bioz Stars, 2021-07
    86/100 stars
      Buy from Supplier

    99
    PeproTech vegf a165
    Vegf A165, supplied by PeproTech, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegf a165/product/PeproTech
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    vegf a165 - by Bioz Stars, 2021-07
    99/100 stars
      Buy from Supplier

    98
    R&D Systems recombinant human vegf a165
    Delivering GFs and laminin HBD peptide enhances skin wound healing. Full-thickness back-skin wounds in 10– 11-week-old C57BLKS/J-m/Lepr db (db/db) mice were treated with combined <t>VEGF-A165</t> (100 ng/wound) and PDGF-BB (50 ng/wound). Four groups were tested: fibrin only, fibrin functionalized with α 2 PI 1–8 -LAMA3 3043–3067 peptide, fibrin containing admixed GFs, and fibrin functionalized with α 2 PI 1–8 -LAMA3 3043–3067 peptide containing GFs. After 4, 7, and 10 days, a , b wound closure and c granulation tissue area were evaluated by histology (means ± SEM, day 4: n = 6, day 7: fibrin only, and α 2 PI 1–8 -LAMA3 3043–3067 peptide + GFs, n = 10; other treatment groups, n = 11, day 10: α 2 PI 1–8 -LAMA3 3043–3067 peptide, n = 8, α 2 PI 1–8 -LAMA3 3043–3067 peptide + GFs, n = 9, and other treatment groups, n = 7). b The proportions of the mice were categorized by the degree of healing after day 7 of wound treatment. d Wound histology (hematoxylin and eosin staining) at day 7. Red arrows indicate tips of the epithelium tongue. The granulation tissue (pink–violet) is characterized by a large number of granulocytes with nuclei that stain in dark-violet or black. Muscle under the wounds is stained in red. Fat tissue appears as transparent bubbles. Scale bar = 800 µm. e – g A total of 5 days after the wound treatment, e proliferation of CD31 + CD45 – endothelial cells is assessed by Ki67 + marker, and f the frequency of Ly6G + CD11b + neutrophils within CD45 + cells and g the frequency of Ly6C + CD11b + monocytes within CD45 + cells were determined using flow cytometry (means ± SEM). * P
    Recombinant Human Vegf A165, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human vegf a165/product/R&D Systems
    Average 98 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    recombinant human vegf a165 - by Bioz Stars, 2021-07
    98/100 stars
      Buy from Supplier

    Image Search Results


    Delivering GFs and laminin HBD peptide enhances skin wound healing. Full-thickness back-skin wounds in 10– 11-week-old C57BLKS/J-m/Lepr db (db/db) mice were treated with combined VEGF-A165 (100 ng/wound) and PDGF-BB (50 ng/wound). Four groups were tested: fibrin only, fibrin functionalized with α 2 PI 1–8 -LAMA3 3043–3067 peptide, fibrin containing admixed GFs, and fibrin functionalized with α 2 PI 1–8 -LAMA3 3043–3067 peptide containing GFs. After 4, 7, and 10 days, a , b wound closure and c granulation tissue area were evaluated by histology (means ± SEM, day 4: n = 6, day 7: fibrin only, and α 2 PI 1–8 -LAMA3 3043–3067 peptide + GFs, n = 10; other treatment groups, n = 11, day 10: α 2 PI 1–8 -LAMA3 3043–3067 peptide, n = 8, α 2 PI 1–8 -LAMA3 3043–3067 peptide + GFs, n = 9, and other treatment groups, n = 7). b The proportions of the mice were categorized by the degree of healing after day 7 of wound treatment. d Wound histology (hematoxylin and eosin staining) at day 7. Red arrows indicate tips of the epithelium tongue. The granulation tissue (pink–violet) is characterized by a large number of granulocytes with nuclei that stain in dark-violet or black. Muscle under the wounds is stained in red. Fat tissue appears as transparent bubbles. Scale bar = 800 µm. e – g A total of 5 days after the wound treatment, e proliferation of CD31 + CD45 – endothelial cells is assessed by Ki67 + marker, and f the frequency of Ly6G + CD11b + neutrophils within CD45 + cells and g the frequency of Ly6C + CD11b + monocytes within CD45 + cells were determined using flow cytometry (means ± SEM). * P

    Journal: Nature Communications

    Article Title: Laminin heparin-binding peptides bind to several growth factors and enhance diabetic wound healing

    doi: 10.1038/s41467-018-04525-w

    Figure Lengend Snippet: Delivering GFs and laminin HBD peptide enhances skin wound healing. Full-thickness back-skin wounds in 10– 11-week-old C57BLKS/J-m/Lepr db (db/db) mice were treated with combined VEGF-A165 (100 ng/wound) and PDGF-BB (50 ng/wound). Four groups were tested: fibrin only, fibrin functionalized with α 2 PI 1–8 -LAMA3 3043–3067 peptide, fibrin containing admixed GFs, and fibrin functionalized with α 2 PI 1–8 -LAMA3 3043–3067 peptide containing GFs. After 4, 7, and 10 days, a , b wound closure and c granulation tissue area were evaluated by histology (means ± SEM, day 4: n = 6, day 7: fibrin only, and α 2 PI 1–8 -LAMA3 3043–3067 peptide + GFs, n = 10; other treatment groups, n = 11, day 10: α 2 PI 1–8 -LAMA3 3043–3067 peptide, n = 8, α 2 PI 1–8 -LAMA3 3043–3067 peptide + GFs, n = 9, and other treatment groups, n = 7). b The proportions of the mice were categorized by the degree of healing after day 7 of wound treatment. d Wound histology (hematoxylin and eosin staining) at day 7. Red arrows indicate tips of the epithelium tongue. The granulation tissue (pink–violet) is characterized by a large number of granulocytes with nuclei that stain in dark-violet or black. Muscle under the wounds is stained in red. Fat tissue appears as transparent bubbles. Scale bar = 800 µm. e – g A total of 5 days after the wound treatment, e proliferation of CD31 + CD45 – endothelial cells is assessed by Ki67 + marker, and f the frequency of Ly6G + CD11b + neutrophils within CD45 + cells and g the frequency of Ly6C + CD11b + monocytes within CD45 + cells were determined using flow cytometry (means ± SEM). * P

    Article Snippet: Recombinant human VEGF-A165 remaining in the fibrinous matrix and in the tissue surrounding the wound was quantified by ELISA (DuoSet, R & D Systems), using 200 ng of recombinant human VEGF-A165 as 100%.

    Techniques: Mouse Assay, Staining, Marker, Flow Cytometry, Cytometry

    Laminin HBD peptides promote cell adhesion in vitro. a , b A total of 3000 cells/well human lung fibroblasts were cultured a without or b with 5 mM EDTA in FGM-2 culture media containing 1% FBS. c , d A total of 3000 cells/well HUVEC were cultured c without or d with 5 mM EDTA in EBM-2 culture media containing 100 ng/mL VEGF-A165 and 1% FBS. Cells were plated on 1 μg/mL laminin peptide pre-coated non-tissue culture-treated plates and incubated for 30 min at 37 °C. After plate washes, cell numbers were quantified using a CyQUANT assay ( n = 10, mean ± SEM). The signals obtained from BSA-coated wells are normalized to 1, and relative fold increases of cell numbers were calculated. Statistical analyses were performed using ANOVA with Tukey’s test. Kruskal–Wallis test followed by Dunn’s multiple comparison was used in b , c . * p

    Journal: Nature Communications

    Article Title: Laminin heparin-binding peptides bind to several growth factors and enhance diabetic wound healing

    doi: 10.1038/s41467-018-04525-w

    Figure Lengend Snippet: Laminin HBD peptides promote cell adhesion in vitro. a , b A total of 3000 cells/well human lung fibroblasts were cultured a without or b with 5 mM EDTA in FGM-2 culture media containing 1% FBS. c , d A total of 3000 cells/well HUVEC were cultured c without or d with 5 mM EDTA in EBM-2 culture media containing 100 ng/mL VEGF-A165 and 1% FBS. Cells were plated on 1 μg/mL laminin peptide pre-coated non-tissue culture-treated plates and incubated for 30 min at 37 °C. After plate washes, cell numbers were quantified using a CyQUANT assay ( n = 10, mean ± SEM). The signals obtained from BSA-coated wells are normalized to 1, and relative fold increases of cell numbers were calculated. Statistical analyses were performed using ANOVA with Tukey’s test. Kruskal–Wallis test followed by Dunn’s multiple comparison was used in b , c . * p

    Article Snippet: Recombinant human VEGF-A165 remaining in the fibrinous matrix and in the tissue surrounding the wound was quantified by ELISA (DuoSet, R & D Systems), using 200 ng of recombinant human VEGF-A165 as 100%.

    Techniques: In Vitro, Cell Culture, Incubation, CyQUANT Assay

    GF retention in fibrin matrices is enhanced by incorporating laminin HBD peptide. a , b GF retention in the fibrin matrix. α 2 PI 1–8 -LAMA3 3043–3067 or α 2 PI 1–8 -LAMA5 3417–3436 peptide-functionalized fibrin matrices were made in the presence of VEGF-A165 or PDGF-BB, and incubated in eight volumes of physiological buffer for 5 days. The buffer was changed each day, and released GFs were quantified daily. The graphs show the cumulative release of a VEGF-A165 or b PDGF-BB over 5 days ( n = 4; mean ± SEM). All data points for laminin HBD peptides were statistically significant compared to controls without laminin HBD peptide ( p

    Journal: Nature Communications

    Article Title: Laminin heparin-binding peptides bind to several growth factors and enhance diabetic wound healing

    doi: 10.1038/s41467-018-04525-w

    Figure Lengend Snippet: GF retention in fibrin matrices is enhanced by incorporating laminin HBD peptide. a , b GF retention in the fibrin matrix. α 2 PI 1–8 -LAMA3 3043–3067 or α 2 PI 1–8 -LAMA5 3417–3436 peptide-functionalized fibrin matrices were made in the presence of VEGF-A165 or PDGF-BB, and incubated in eight volumes of physiological buffer for 5 days. The buffer was changed each day, and released GFs were quantified daily. The graphs show the cumulative release of a VEGF-A165 or b PDGF-BB over 5 days ( n = 4; mean ± SEM). All data points for laminin HBD peptides were statistically significant compared to controls without laminin HBD peptide ( p

    Article Snippet: Recombinant human VEGF-A165 remaining in the fibrinous matrix and in the tissue surrounding the wound was quantified by ELISA (DuoSet, R & D Systems), using 200 ng of recombinant human VEGF-A165 as 100%.

    Techniques: Incubation

    Laminin binds promiscuously to GFs and chemokines. a Binding of multiple isoforms of full-length laminin (–111, –211, –332, –411, –421, –511, and –521) to GFs and CXCL chemokines were measured by ELISA. A450 nm represents absorbance at 450 nm. BSA-coated wells served as negative controls ( n = 4, mean ± SEM). Signals greater than 0.1 (gray box) are considered to be significant. b Affinities ( K D values are shown) of full-length laminin against VEGF-A165, PlGF-2, and PDGF-BB were measured by SPR. A SPR chip was functionalized with laminin-521 (~2000 resonance units (RU)), and each GF was flown over the chip at indicated concentrations. Curves represent the specific responses (in RU) to laminin obtained. Experimental curves were fitted with Langmuir binding kinetics. Binding kinetics values [dissociation constants ( K D ) and rate constants ( K on and K off )] determined from the fitted curves are shown. Two experimental replicates

    Journal: Nature Communications

    Article Title: Laminin heparin-binding peptides bind to several growth factors and enhance diabetic wound healing

    doi: 10.1038/s41467-018-04525-w

    Figure Lengend Snippet: Laminin binds promiscuously to GFs and chemokines. a Binding of multiple isoforms of full-length laminin (–111, –211, –332, –411, –421, –511, and –521) to GFs and CXCL chemokines were measured by ELISA. A450 nm represents absorbance at 450 nm. BSA-coated wells served as negative controls ( n = 4, mean ± SEM). Signals greater than 0.1 (gray box) are considered to be significant. b Affinities ( K D values are shown) of full-length laminin against VEGF-A165, PlGF-2, and PDGF-BB were measured by SPR. A SPR chip was functionalized with laminin-521 (~2000 resonance units (RU)), and each GF was flown over the chip at indicated concentrations. Curves represent the specific responses (in RU) to laminin obtained. Experimental curves were fitted with Langmuir binding kinetics. Binding kinetics values [dissociation constants ( K D ) and rate constants ( K on and K off )] determined from the fitted curves are shown. Two experimental replicates

    Article Snippet: Recombinant human VEGF-A165 remaining in the fibrinous matrix and in the tissue surrounding the wound was quantified by ELISA (DuoSet, R & D Systems), using 200 ng of recombinant human VEGF-A165 as 100%.

    Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, SPR Assay, Chromatin Immunoprecipitation

    Excess heparin inhibits GF–laminin binding. Inhibition of GF-binding to laminin (–111, –211, –221, –411, –421, –511, and –521) by excess heparin. ELISA plates were coated with 10 µg/mL laminin and further incubated with 1 μg/mL a VEGF-A165, b PlGF-2, or c FGF-2 solution in the absence or presence of excess (10 μM) heparin. Bound GFs were detected using a specific antibody for each GF ( n = 4, mean ± SEM). Statistical analyses were performed using the Mann–Whitney U test by comparing the signals with and without heparin. * p

    Journal: Nature Communications

    Article Title: Laminin heparin-binding peptides bind to several growth factors and enhance diabetic wound healing

    doi: 10.1038/s41467-018-04525-w

    Figure Lengend Snippet: Excess heparin inhibits GF–laminin binding. Inhibition of GF-binding to laminin (–111, –211, –221, –411, –421, –511, and –521) by excess heparin. ELISA plates were coated with 10 µg/mL laminin and further incubated with 1 μg/mL a VEGF-A165, b PlGF-2, or c FGF-2 solution in the absence or presence of excess (10 μM) heparin. Bound GFs were detected using a specific antibody for each GF ( n = 4, mean ± SEM). Statistical analyses were performed using the Mann–Whitney U test by comparing the signals with and without heparin. * p

    Article Snippet: Recombinant human VEGF-A165 remaining in the fibrinous matrix and in the tissue surrounding the wound was quantified by ELISA (DuoSet, R & D Systems), using 200 ng of recombinant human VEGF-A165 as 100%.

    Techniques: Binding Assay, Inhibition, Enzyme-linked Immunosorbent Assay, Incubation, MANN-WHITNEY

    GFs bind to laminin HBD derived from LAMA3, LAMA4, and LAMA5. a The location of laminin-derived peptides in the LG domain of LAMA3, LAMA4, and LAMA5 chains. b–f Affinity of heparin and GFs against chemically synthesized peptides derived from the LG domain of LAMA3, LAMA4, and LAMA5 chains. ELISA plates were coated with 10 µg/mL laminin peptide and further incubated with b biotinylated heparin, c VEGF-A165 and VEGF-A121, d PlGF-2 and PlGF-1, e PDGF-BB, or f FGF-2. Concentrations were 1 μg/mL for GFs and 10 µg/mL for heparin. Bound heparin was detected with streptavidin, and bound GFs with a specific antibody for each GF ( n = 4, mean ± SEM). Statistical analyses were performed using the Mann–Whitney U test by comparing the signals obtained from the laminin peptide- and the BSA-coated wells. * p

    Journal: Nature Communications

    Article Title: Laminin heparin-binding peptides bind to several growth factors and enhance diabetic wound healing

    doi: 10.1038/s41467-018-04525-w

    Figure Lengend Snippet: GFs bind to laminin HBD derived from LAMA3, LAMA4, and LAMA5. a The location of laminin-derived peptides in the LG domain of LAMA3, LAMA4, and LAMA5 chains. b–f Affinity of heparin and GFs against chemically synthesized peptides derived from the LG domain of LAMA3, LAMA4, and LAMA5 chains. ELISA plates were coated with 10 µg/mL laminin peptide and further incubated with b biotinylated heparin, c VEGF-A165 and VEGF-A121, d PlGF-2 and PlGF-1, e PDGF-BB, or f FGF-2. Concentrations were 1 μg/mL for GFs and 10 µg/mL for heparin. Bound heparin was detected with streptavidin, and bound GFs with a specific antibody for each GF ( n = 4, mean ± SEM). Statistical analyses were performed using the Mann–Whitney U test by comparing the signals obtained from the laminin peptide- and the BSA-coated wells. * p

    Article Snippet: Recombinant human VEGF-A165 remaining in the fibrinous matrix and in the tissue surrounding the wound was quantified by ELISA (DuoSet, R & D Systems), using 200 ng of recombinant human VEGF-A165 as 100%.

    Techniques: Derivative Assay, Synthesized, Enzyme-linked Immunosorbent Assay, Incubation, MANN-WHITNEY

    GFs bind to LG domain derived from LAMA3, LAMA4, and LAMA5. Affinity of GFs against recombinant laminin LG domains. ELISA plates were coated with 1 µg/mL a LAMA3 2928–3150 , b LAMA4 826–1816 , or c LAMA5 3026–3482 and further incubated with 1 μg/mL of VEGF-A165, VEGF-A121, PlGF-2, PlGF-1, PDGF-BB, or FGF-2 solution. Bound GFs were detected using a specific antibody for each GF ( n = 4, mean ± SEM). Statistical analyses were performed using the Mann–Whitney U test by comparing the signals obtained from the laminin domain- and the BSA-coated wells. * p

    Journal: Nature Communications

    Article Title: Laminin heparin-binding peptides bind to several growth factors and enhance diabetic wound healing

    doi: 10.1038/s41467-018-04525-w

    Figure Lengend Snippet: GFs bind to LG domain derived from LAMA3, LAMA4, and LAMA5. Affinity of GFs against recombinant laminin LG domains. ELISA plates were coated with 1 µg/mL a LAMA3 2928–3150 , b LAMA4 826–1816 , or c LAMA5 3026–3482 and further incubated with 1 μg/mL of VEGF-A165, VEGF-A121, PlGF-2, PlGF-1, PDGF-BB, or FGF-2 solution. Bound GFs were detected using a specific antibody for each GF ( n = 4, mean ± SEM). Statistical analyses were performed using the Mann–Whitney U test by comparing the signals obtained from the laminin domain- and the BSA-coated wells. * p

    Article Snippet: Recombinant human VEGF-A165 remaining in the fibrinous matrix and in the tissue surrounding the wound was quantified by ELISA (DuoSet, R & D Systems), using 200 ng of recombinant human VEGF-A165 as 100%.

    Techniques: Derivative Assay, Recombinant, Enzyme-linked Immunosorbent Assay, Incubation, MANN-WHITNEY